Approach for identifying of treatment option for pediatric patients in Guillain—Barre syndrome considering results of pharmacoeconomic analysis

Shakarian A.K.; Rakhteenko A.V.; Yagudina R.I.; Kulikov A.Yu.; Serpik V.G.; Mitrofanova I.V.

doi:https://doi.org/10.17116/jnevro20181183139-45

Shakarian A.K.

Rakhteenko A.V.

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia

Yagudina R.I.

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russia, Moscow, Russia

Kulikov A.Yu.

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russia, Moscow, Russia

Serpik V.G.

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russia, Moscow, Russia

Mitrofanova I.V.

Municipal Clinical Hospital №1, Department of Health Care, Moscow, Russia

Approach for identifying of treatment option for pediatric patients in Guillain—Barre syndrome considering results of pharmacoeconomic analysis

Authors:

Shakarian A.K., Rakhteenko A.V., Yagudina R.I., Kulikov A.Yu., Serpik V.G., Mitrofanova I.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(3): 39‑45

DOI: 10.17116/jnevro20181183139-45

Read: 1684 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Shakarian AK, Rakhteenko AV, Yagudina RI, Kulikov AYu, Serpik VG, Mitrofanova IV. Approach for identifying of treatment option for pediatric patients in Guillain—Barre syndrome considering results of pharmacoeconomic analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(3):39‑45. (In Russ.)
https://doi.org/10.17116/jnevro20181183139-45

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Modern approaches to diagnosis and treatment of postinfectious asthenic syndrome in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):42-52

Pathogenetic aspects of autoantibody formation to central nervous system structures in patients with encephalitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):53-58

Stress and sleep: Neurobiological aspects and modern options of insomnia therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):14-21

Insomnia in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):46-51

Early diagnosis and effective therapy of diabetic polyneuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):62-68

Risk factors of unfavorable outcome after decompressive craniectomy in children with severe traumatic brain injury. Burdenko's Journal of Neurosurgery. 2025;(3):42-47

Pathomorphology of chronic polypous purulent rhinosinusitis in cystic fibrosis in children. Russian Rhinology. 2025;(2):101-110

Chronic obstructive pulmonary disease (COPD 2024). Clinical guidelines (short version). Journal of Respiratory Medicine. 2025;(2):5-16

Portopulmonary hypertension. Journal of Respiratory Medicine. 2025;(2):39-44

Diagnosis and treatment of ovarian cancer in pregnancy. Russian Bulletin of Obstetrician-Gynecologist. 2025;(3):27-33

Abstract:

Objective. A pharmacoeconomic analysis of direct costs on treatment with high dose intravenous immunoglobulins (IVIG) and plasmapheresis (PP) in children. Material and methods. Literature data on the pathogenesis of Guillain—Barre syndrome (GBS) were analyzed. The results of pharmacoeconomic analysis of direct costs on treatment of GBS using IVIG and PP are presented. Risks for complications during treatment with IVIG and PP are calculated. Results and conclusion. The pharmacoeconomic analysis demonstrates comparable costs of treatment with IVIG or PP in the Russian Federation. Nevertheless, a less number of complications, convenience in use and the good safety and tolerability profile make it more preferable to this group of patients. In a clinical case of a 7-year child described in the article, treatment with 10% IVIG — privigen in dose 2 g/kg during 5 days started in the 3rd week of disease showed a marked positive effect.

Keywords:

Guillain—Barre syndrom

treatment

IVIG

plasmapheresis

privigen

children

pharmacoeconomics

direct costs

Authors:

Shakarian A.K.

Rakhteenko A.V.

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia

Yagudina R.I.

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russia, Moscow, Russia

Kulikov A.Yu.

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russia, Moscow, Russia

Serpik V.G.

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russia, Moscow, Russia

Mitrofanova I.V.

Municipal Clinical Hospital №1, Department of Health Care, Moscow, Russia

Close metadata

References:

Goodfellow JA, Willison HJ. Guillain—Barré syndrome: A century of progress. Nat Rev Neurol. 2016;12(12):723-731. https://doi.org/10.1038/nrneurol.2016.172
McGrogan A, Madle GC, Seaman HE, De Vries CS. The epidemiology of Guillain-Barre syndrome worldwide: A systematic literature review. Neuroepidemiology. 2009;32(2):150-163. https://doi.org/10.1159/000184748
Willison HJ, Jacobs BC, van Doorn PA. Guillain—Barré syndrome. The Lancet. 2016;388(10045):717-727. https://doi.org/10.1016/s0140-6736(16)00339-1
Hughes RA, Cornblath DR. Guillain—Barré syndrome. Lancet. 2005; 366(9497):1653-1666. https://doi.org/10.1016/s0140-6736(05)67665-9
Marx А, Glass JD, Sutter RW. Differential diagnosis of acute flaccid paralysis and its role in poliomyelitis surveillance. Epidemiol Rev. 2000;22(2):298-316. https://doi.org/10.1093/oxfordjournals.epirev.a018041
Suponeva NA, Shakaryan AK, Rakhteenko AV, Piradov MA, Mitrofanova IV, Prytkova MI, Leont’ieva IY, Shakhgildyan SV, Morozova NS. Clinical and Laboratory Features, Treatment and Prognosis in Children with Guillian—Barre Syndrome. Children Infections. 2015;14(3):17-26. (In Russ.) https://doi.org/10.22627/2072-8107-2015-14-3-17-26.
Brasil P, Sequeira PC, Freitas AD, Zogbi HE, Calvet GA, de Souza RV, Siqueira AM, de Mendonca MCL, Nogueira RMR, de Filippis AMB, Solomon T. Guillain—Barré syndrome associated with Zika virus infection. Lancet. 2016;10026:1482. https://doi.org/10.1016/s0140-6736(16)30058-7
Cao-Lormeau V-M, Blake A, Mons S, Lastère S, Roche C, Vanhomwegen J, Dub T, Baudouin L, Teissier A, Larre P, Vial A-L, Decam C, Choumet V, Halstead SK, Willison HJ, Musset L, Manuguerra J-C, Despres P, Fournier E, Mallet H-P, Musso D, Fontanet A, Neil J, Ghawché F. Guillain—Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531-1539. https://doi.org/10.1016/s0140-6736(16)00562-6
Uncini A, Shahrizaila N, Kuwabara S. Zika virus infection and Guillain—Barré syndrome: a review focused on clinical and electrophysiological subtypes. J Neurol Neurosurg Psychiatry. 2017;88(3):266-271. https://doi.org/10.1136/jnnp-2016-314310
Dos Santos T, Rodriguez A, Almiron M, Sanhueza A, Ramon P, de Oliveira WK, Coelho GE, Badaró R, Cortez J, Ospina M, Pimentel R, Masis R, Hernandez F, Lara B, Montoya R, Jubithana B, Melchor A, Alvarez A, Aldighieri S, Dye C, Espinal MA. Zika Virus and the Guillain—Barré Syndrome — Case Series from Seven Countries. N Engl J Med. 2016;20; 375(16):1598-1601. https://doi.org/10.1056/nejmc1609015
Estridge R, Iskander M. Understanding Guillain—Barré syndrome. JAAPA. 2015;28(7):19-22. https://doi.org/10.1097/01.jaa.0000466585.10595.f5
Piradov MA, Suponeva NA. Gullian—Barre syndrome: diagnostic and treatment. M. 2011. (In Russ.)
Winer JB. Guillain—Barre syndrome: Clinical variants and their pathogenesis. J Neuroimmunol. 2011;231(1-2):70-72. https://doi.org/10.1016/j.jneuroim.2010.09.017
Federal clinical recommendations for children with Guillain—Barre syndrome. Ministerstvo zdravookhraneniya Rossiyskoy Federatsii, Soyuz Pediatrov Rossii. 2015. (In Russ.)
Hughes RA, van Doorn PA. Corticosteroids for Guillain—Barre syndrome. Cochrane Database Syst Rev. 2012;8:CD001446. https://doi.org/10.1002/14651858.cd001446
Hughes RAC, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain—Barré syndrome. Cochrane Database of Systematic Reviews. 2016;10:CD001446. https://doi.org/10.1002/14651858.cd001446.pub5
Plasma Exchange/Sandoglobulin Guillain—Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain—Barré syndrome. Lance. 1997;349(9047): 225-230. https://doi.org/10.1016/s0140-6736(96)09095-2
Hughes RA, Swan AV, van Doorn P. Intravenous immunoglobulin for Guillain—Barré syndrome. Cochrane Database Syst Rev. 2014;9:CD002063. https://doi.org/10.1002/14651858.cd002063.pub6
Looney RJ, Huggins J. Use of intravenous immunoglobulin G (IVIG). Best Pract Res Clin Haematol. 2006;19:3-25. https://doi.org/10.1016/j.beha.2005.01.032
Bolli R, Woodtli K, Bärtschi M, Höfferer L, Lerch P. l-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biologicals. 2010;38(1):150-157. https://doi.org/10.1016/j.biologicals.2009.09.002
Raphaël JC, Chevret S, Hughes RAC, Annane D. Plasma exchange for Guillain—Barré syndrome. Cochrane Database Syst Rev. 2012;7:CD001798. https://doi.org/10.1002/14651858.cd001798.pub2
Harms M. Inpatient management of Guillain—Barre syndrome. Neurohospitalist. 2011;1(2):78-84. https://doi.org/10.1177/1941875210396379
Meena AK, Khadilkar SV, Murthy JMK. Treatment guidelines for Guillain—Barré Syndrome. Ann Indian Acad Neurol. 2011;14(suppl 1):73-81. https://doi.org/10.4103/0972-2327.83087
Ullman AJ, Marsh N, Mihala G, Cooke M, Rickard CM. Complications of Central Venous Access Devices: A Systematic Review. Pediatrics. 2015; 136(5):1331-1344. https://doi.org/10.1542/peds.2015-1507
Shemin D, Briggs D, Greenan M. Complications of therapeutic plasma exchange: A prospective study of 1,727 procedures. J Clin Apher. 2007;22(5): 270-276. https://doi.org/10.1002/jca.20143
Prilozhenie №8.1. k Tarifnomu soglasheniyu na 2017 g. ot 29.12.2016. Moskovskii fond obyazatel'nogo meditsinskogo strakhovaniya. http://mfoms.ru
Nosadini M, Mohammad SS, Suppiej A, Sartori S, Dale RC, Barclay P, Koh Y, Teo J, Tantsis EM, Ramanathan S, Webster R. Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and long-term outcome. Dev Med Child Neurol. 2016;58(11):1180-1192. https://doi.org/10.1111/dmcn.13159